The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared to the drug prednisone. In the trial known as COMET-1, Cabozantinib, a tyrosine kinase inhibitor, did not meet its primary [...]
I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute. The award recognizes outstanding dedication and support to the prostate cancer community. I am pleased and flattered to be one of this year's receptients.I have been told that one reason I have received this [...]
Advanced prostate cancer and its treatments has significant impacts on a man’s quality of life (QOL) as well as their perception of their health. It is important to better understand these concerns, especially those currently not captured by the currently available health-related quality of life (HRQL) instruments. In the quest to better understand these concerns [...]
Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel. Since its FDA approval post chemotherapy there has [...]
Clouded in the murkiness of the debate surrounding the use of the PSA test is an increasing escalation of younger men (under the age of 50 years) being diagnosed with advanced prostate cancer. We know that there has been escalating incidence rate (IR) of prostate cancer PC noted in the last two decades. Many have [...]